Search

Your search keyword '"Trippa, F"' showing total 142 results
Start Over Author "Trippa, F" Publication Year Range Last 10 years
142 results on '"Trippa, F"'

3. STereotactic Ablative RadioTherapy in NEWly Diagnosed and Recurrent Locally Advanced Non-Small Cell Lung Cancer Patients Unfit for ConcurrEnt RAdio-Chemotherapy: Early Analysis of the START-NEW-ERA Non-Randomised Phase II Trial

Author

Arcidiacono, F., Anselmo, P., Casale, M., Zannori, C., Ragusa, M., Mancioli, F., Marchetti, G., Loreti, F., Italiani, M., Bracarda, S., Maranzano, E., and Trippa, F.

Subjects
Cancer Research, Radiation, Oncology, Radiology, Nuclear Medicine and imaging
Abstract

This is a single arm phase 2 trial (Clinical trials.gov NCT05291780) to assess local control (LC) and safety of SAbR in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) unfit for concurrent chemo-radiation therapy (ChT-RT).Neoadjuvant ChT was prescribed in fit patients. The tumor volume included primary tumor and any regionally positive node/s. The coprimary study endpoints were LC and safety.Between December 31, 2015, and December 31, 2020, 50 patients with LA-NSCLC were enrolled. Histology was squamous cell carcinoma and adenocarcinoma (ADC) in 52% and 48%, respectively. Forty (80%) patients had ultracentral tumor. Twenty-seven (54%) received neoadjuvant ChT and 7 (14%) adjuvant durvalumab. Median prescribed dose was 45 Gy (range, 35-55) and 40 Gy (35-45) in 5 daily fractions to tumor and node/s, respectively. After a median follow-up of 38 months (range, 12-80), 19 (38%) patients had experienced local recurrence (LR) at a median time of 13 months (range, 7-34). The median LR-free survival (FS) was not reached (95% confidence interval [CI], 28 to not reached). The 1-, 2-, and 3-year LR-FS rates were 86% ± 5%, 66% ± 7%, and 56% ± 8%, respectively. At last follow-up, 33 (66%) patients were alive. Median overall survival (OS) was 55 months (95% CI, 43-55 months). The 1-, 2-, and 3-year OS rates were 94% ± 3%, 79% ± 6%, and 72% ± 7%, respectively. No patients developed ≥ grade (G) 3 toxicity. ADC (hazard ratio [HR], 3.61; 95% CI, 1.15-11.35) was a significant predictor of better LC, while OS was significantly conditioned by smaller planning target volumes (HR, 1.004; 95% CI, 1.001-1.010) and tumor, node, and metastasis stage (HR, 4.8; 95% CI, 1.34-17).Patients with LA-NSCLC treated with SABR had optimal LC and promising OS in absence of ≥G3 toxicity. Our early outcomes would suggest the feasibility of using this approach in patients with LA-NSCLC unfit for concurrent ChT-RT.

Published
2023

6. OC-0763 SAbR in LA-NSCLC patients unfit for concurrent ChT-RT: START-NEW-ERA non-randomised phase II trial

Author

Arcidiacono, F., primary, Anselmo, P., additional, Casale, M., additional, Zannori, C., additional, Loreti, F., additional, Ragusa, M., additional, Enrico, B., additional, Mancioli, F., additional, Marchetti, G., additional, Italiani, M., additional, Fabiani, S., additional, Guida, A., additional, Tassi, V., additional, Caprera, C., additional, Corsi, M., additional, Bracarda, S., additional, Maranzano, E., additional, and Trippa, F., additional

Published
2023
Full Text
View/download PDF

9. 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)

Author

Macchia, G, Lazzari, R, Colombo, N, Laliscia, C, Capelli, G, D’Agostino, GR, Deodato, F, Trippa, F, Ippolito, E, Ronchi, S, Pajar, F, Scorsetti, M, Cilla, S, Ingargiola, R, Huscher, A, Cerrotta, AM, Andrei, F, Vicenzi, L, Russo, D, Borghesi, S, Perrucci, E, Pignata, S, Aristei, C, Morganti, AG, Scambia, G, Valentini, V, Jereczek-Fossa, BA, and Ferrandina, G

Published
2019
Full Text
View/download PDF

10. Salvage Radiotherapy Guided by Functional Imaging for Macroscopic Local Recurrence Following Radical Prostatectomy: A Multicentric Retrospective Study

Author

Benziane-Ouaritini, N., primary, Zilli, T., additional, Ingrosso, G., additional, di Staso, M., additional, Trippa, F., additional, Francolini, G., additional, Meyer, E., additional, Achard, V.M., additional, Schick, U., additional, Cosset, J.M., additional, Martin, E., additional, Penna, R. Renard, additional, Ferrari, V., additional, Giraud, N., additional, Pasquier, C., additional, Magne, N., additional, Anger, E., additional, Aristei, C., additional, Perrenec, T., additional, Gnep, K., additional, Pasquier, D., additional, Supiot, S., additional, Sargos, P., additional, and Latorzeff, I., additional

Published
2022
Full Text
View/download PDF

14. OC-0607 Radiotherapy guided by functional imaging for macroscopic local recurrence following prostatectomy

Author

Benziane, N., primary, Sargos, P., additional, Zilli, T., additional, Giraud, A., additional, Ingrosso, G., additional, Di Staso, M., additional, Trippa, F., additional, Meyer, E., additional, Francolini, G., additional, Schick, U., additional, Cosset, J.M., additional, Martin, E., additional, Ferrari, V., additional, Achard, V., additional, Giraud, N., additional, Pasquier, C., additional, Magné, N., additional, Pasquier, D., additional, Supiot, S., additional, Latorzeff, I., additional, Gnep, K., additional, Pommier, P., additional, Perennec, T., additional, and Zaine, H., additional

Published
2022
Full Text
View/download PDF

16. Stereotactic radiotherapy for oligometastases in the lymph nodes

Author

Pasqualetti, F., Trippa, F., Aristei, C., Borghesi, S., Colosimo, C., Cantarella, M., Mazzola, R., and Ingrosso, G.

Subjects
Oligometastasis, Toxicity, Oncology, Local control, Stereotactic radiotherapy, Hypofractionation, Radiology, Nuclear Medicine and imaging, Bed, Organ motion, Radiosurgery, Lymph node metastases
Abstract

Even though systemic therapy is standard treatment for lymph node metastases, metastasis-directed stereotactic radiotherapy (SRT ) seems to be a valid option in oligometastatic patients with a low disease burden. Positron emission tomography-computed tomography (PET-CT ) is the gold standard for assessing metastases to the lymph nodes; co-registration of PET-CT images and planning CT images are the basis for gross tumor volume (GTV ) delineation. Appropriate techniques are needed to overcome target motion. SRT schedules depend on the irradiation site, target volume and dose constraints to the organs at risk (OARs) of toxicity. Although several fractionation schemes were reported, total doses of 48-60 Gy in 4-8 fractions were proposed for mediastinal lymph node SRT, with the spinal cord, esophagus, heart and proximal bronchial tree being the dose limiting OAR s. Total doses ranged from 30 to 45 Gy, with daily fractions of 7-12 Gy for abdominal lymph nodes, with dose limiting OARs being the liver, kidneys, bowel and bladder. SRT on lymph node metastases is safe; late side effects, particularly severe, are rare.

Published
2021

20. 126P Chemotherapy and stereotactic ablative radiotherapy in newly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrent radiochemotherapy: Sub-analysis and update of START-NEW-ERA non-randomised phase II trial

Author

Arcidiacono, F., Anselmo, P., Casale, M., Zannori, C., Loreti, F., Italiani, M., Enrico, B., Fabiani, S., Marchetti, G., Tassi, V., Mancioli, F.A., Muti, M., Guida, A., Bracarda, S., Ragusa, M., Maranzano, E., and Trippa, F.

Published
2023
Full Text
View/download PDF

23. PH-0118: Stereotactic or conventional RT for macroscopic prostate bed recurrence: a propensity score analysis

Author

Francolini, G., primary, Jereczek-Fossa, B.A., additional, Di Cataldo, V., additional, Simontacchi, G., additional, Marvaso, G., additional, Zerella, M.A., additional, Gentile, P., additional, Bianciardi, F., additional, Allegretta, S., additional, Detti, B., additional, Masi, L., additional, Ciccone, L.P., additional, Bruni, A., additional, Ingrosso, G., additional, Mazzeo, E., additional, Trippa, F., additional, Lohr, F., additional, and Livi, L., additional

Published
2020
Full Text
View/download PDF

24. Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Cannoletta, C., primary, Fossati, N., additional, Karnes, R., additional, Heidenreich, A., additional, Stief, C., additional, Battaglia, A., additional, Joniau, S., additional, Osmonov, D., additional, Shariat, S., additional, Albers, P., additional, Tilki, D., additional, Gill, I., additional, Mottrie, A., additional, Jereczek-Fossa, B., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, De Iturriaga, A., additional, Trippa, F., additional, Detti, B., additional, and Ost, P., additional

Published
2019
Full Text
View/download PDF

25. 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)

Author

Macchia, G, primary, Lazzari, R, additional, Colombo, N, additional, Laliscia, C, additional, Capelli, G, additional, D’Agostino, GR, additional, Deodato, F, additional, Trippa, F, additional, Ippolito, E, additional, Ronchi, S, additional, Pajar, F, additional, Scorsetti, M, additional, Cilla, S, additional, Ingargiola, R, additional, Huscher, A, additional, Cerrotta, AM, additional, Andrei, F, additional, Vicenzi, L, additional, Russo, D, additional, Borghesi, S, additional, Perrucci, E, additional, Pignata, S, additional, Aristei, C, additional, Morganti, AG, additional, Scambia, G, additional, Valentini, V, additional, Jereczek-Fossa, BA, additional, and Ferrandina, G, additional

Published
2019
Full Text
View/download PDF

32. Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Fossati, N., primary, Karnes, R.J., additional, Heidenreich, A., additional, Stief, C., additional, Battaglia, A., additional, Joniau, S., additional, Osmonov, D., additional, Shariat, S., additional, Albers, P., additional, Tilki, D., additional, Gill, I.S., additional, Mottrie, A., additional, Jereczek-Fossa, B.A., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, De Iturriaga, A.G., additional, Trippa, F., additional, Detti, B., additional, and Ost, P., additional

Published
2019
Full Text
View/download PDF

33. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

Author

De Bleser, E., primary, Jereczek-Fossa, B.A., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, Gomez De Iturriaga, A., additional, Trippa, F., additional, Detti, B., additional, Ingrosso, G., additional, Triggiani, L., additional, Alessio, B., additional, Alongi, F., additional, Reynders, D., additional, Fonteyne, V., additional, Surgo, A., additional, Loukili, K., additional, Miralbell, R., additional, Silva, P., additional, Chander, S., additional, Goetghebeur, E., additional, and Ost, P., additional

Published
2019
Full Text
View/download PDF

34. Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis

Author

De Bleser, E., primary, Jereczek-Fossa, B.A., additional, Pasquier, D., additional, Zilli, T., additional, Van As, N., additional, Siva, S., additional, Fodor, A., additional, Dirix, P., additional, Gomez De Iturriaga, A., additional, Trippa, F., additional, Detti, B., additional, Ingrosso, G., additional, Triggiani, L., additional, Alessio, B., additional, Alongi, F., additional, Fonteyne, V., additional, Surgo, A., additional, Loukili, K., additional, Miralbell, R., additional, Pedro, S., additional, Chander, S., additional, Di Muzio, N.G., additional, Francolini, G., additional, Lancia, A., additional, Tree, A., additional, and Ost, P., additional

Published
2018
Full Text
View/download PDF

37. SC189 - Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Cannoletta, C., Fossati, N., Karnes, R., Heidenreich, A., Stief, C., Battaglia, A., Joniau, S., Osmonov, D., Shariat, S., Albers, P., Tilki, D., Gill, I., Mottrie, A., Jereczek-Fossa, B., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., De Iturriaga, A., Trippa, F., Detti, B., and Ost, P.

Published
2019
Full Text
View/download PDF

38. 772 - Imaging targeted treatments versus extended salvage lymph node dissection for patients with a single nodal recurrence of prostate cancer: A comparative analysis from a large multi-institutional series

Author

Fossati, N., Karnes, R.J., Heidenreich, A., Stief, C., Battaglia, A., Joniau, S., Osmonov, D., Shariat, S., Albers, P., Tilki, D., Gill, I.S., Mottrie, A., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., De Iturriaga, A.G., Trippa, F., Detti, B., and Ost, P.

Published
2019
Full Text
View/download PDF

39. 771 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: A multi-institutional analysis

Author

De Bleser, E., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez De Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Alessio, B., Alongi, F., Reynders, D., Fonteyne, V., Surgo, A., Loukili, K., Miralbell, R., Silva, P., Chander, S., Goetghebeur, E., and Ost, P.

Published
2019
Full Text
View/download PDF

45. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy

Author

Luca Marinelli, Giulio Francolini, Stefano Maria Magrini, Daniela Musio, Maurizio Valeriani, Alessio Bruni, Beatrice Detti, Ernesto Maranzano, Saverio Caini, Cynthia Aristei, N. Di Muzio, Andrei Fodor, Andrea Lancia, Simona Borghesi, Gianluca Ingrosso, D. Russo, Fabio Trippa, Lorenzo Livi, Luca Triggiani, Ingrosso, G., Detti, B., Fodor, A., Caini, S., Borghesi, S., Triggiani, L., Trippa, F., Russo, D., Bruni, A., Francolini, G., Lancia, A., Marinelli, L., Di Muzio, N., Livi, L., Magrini, S. M., Maranzano, E., Musio, D., Aristei, C., and Valeriani, M.

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Oligoprogression, medicine.drug_class, Stereotactic body radiotherapy, medicine.medical_treatment, Kaplan-Meier Estimate, Radiosurgery, Targeted therapy, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Internal medicine, Androgen Receptor Antagonists, medicine, Humans, Molecular Targeted Therapy, Survival analysis, Androgen receptor-targeted therapy, Aged, Retrospective Studies, Analysis of Variance, business.industry, Metastatic castration-resistant prostate cancer, NEST-free survival, Hazard ratio, Radiotherapy Dosage, Common Terminology Criteria for Adverse Events, General Medicine, Middle Aged, Androgen, medicine.disease, Combined Modality Therapy, Progression-Free Survival, Radiation therapy, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, Disease Progression, business
Abstract

Objectives: To report outcomes of stereotactic body radiotherapy (SBRT) in metastatic castration-resistant prostate cancer (mCRPC) patients with oligoprogression (≤ 5 metastases) during first-line treatment with androgen receptor-targeted therapy (ARTT). Patients and methods: Retrospective multi-institutional analysis of mCRPC patients treated with SBRT to oligoprogressive lesions during ARTT. End-points were time to next-line systemic treatment (NEST), radiological progression-free survival (r-PFS) and overall survival (OS). Toxicity was registered according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Survival analysis was performed using the Kaplan–Meier method, univariate and multivariate analysis (MVA) were performed. Results: Data from 34 patients were analyzed. Median NEST-free survival, r-PFS, and OS were 16.97, 13.47, and 38.3months, respectively. At MVA, factors associated with worse NEST-free survival and r-PFS were polymetastatic burden at diagnosis of metastatic hormone-sensitive disease (hazard ratio [HR] 3.66, p = 0.009; HR 3.03, p = 0.034), PSA ≤ 7ng/ml at mCRPC diagnosis (HR 0.23, p = 0.017; HR 0.19, p = 0.006) and PSADT ≤ 3months at mCRPC diagnosis (HR 3.39, p = 0.026; HR 2.79, p = 0.037). Polymetastatic state at mHSPC diagnosis was associated with a decreased OS (HR 4.68, p = 0.029). No patient developed acute or late grade ≥ 2 toxicity. Conclusion: Our results suggest that SBRT in oligoprogressive mCPRC is safe, effective and seems to prolong the efficacy of the ongoing systemic treatment positively affecting disease progression. Prospective trials are needed.

Published
2021

46. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy

Author

Giulia Marvaso, Raymond Miralbell, Alfonso Gomez-Iturriaga, Elise De Bleser, Nicholas van As, Chiara Lucrezia Deantoni, Shankar Siva, Giulio Francolini, Beatrice Detti, Els Goetghebeur, Fabio Trippa, Piet Ost, Sarat Chander, Pedro Silva, Alison Tree, Ernesto Maranzano, Alessia Surgo, Filippo Alongi, Gert De Meerleer, Kaoutar Loukili, Luca Triggiani, Dries Reynders, Thomas Zilli, Nadia Di Muzio, Andrea Lancia, Piet Dirix, Barbara Alicja Jereczek-Fossa, Alessio Bruni, Andrei Fodor, David Pasquier, Gianluca Ingrosso, Elisabetta Ponti, De Bleser, E., Jereczek-Fossa, B. A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez-Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Bruni, A., Alongi, F., Reynders, D., De Meerleer, G., Surgo, A., Loukili, K., Miralbell, R., Silva, P., Chander, S., Di Muzio, N. G., Maranzano, E., Francolini, G., Lancia, A., Tree, A., Deantoni, C. L., Ponti, E., Marvaso, G., Goetghebeur, E., and Ost, P.

Subjects
Male, medicine.medical_specialty, Elective nodal radiotherapy, Metastasis-directed therapy, Oligometastasis, Oligorecurrence, Prostatic neoplasms, Radiotherapy, Recurrence, Stereotactic ablative body radiotherapy, Stereotactic body radiotherapy, Urology, medicine.medical_treatment, 030232 urology & nephrology, Radiosurgery, ddc:616.0757, Metastasis, Androgen deprivation therapy, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Interquartile range, Clinical endpoint, Medicine, Humans, Aged, Retrospective Studies, business.industry, Prostatectomy, Prostatic Neoplasms, Middle Aged, medicine.disease, Radiation therapy, Treatment Outcome, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Radiology, Human medicine, Neoplasm Recurrence, Local, business
Abstract

Background: Stereotactic body radiotherapy (SBRT) and elective nodal radiotherapy (ENRT) are being investigated as metastasis-directed treatments in oligorecurrent prostate cancer (PC); however, comparative data are still lacking. Objective: To compare outcome and toxicity between both treatments. Primary endpoint was metastasis-free survival, adjusted for selected variables (aMFS). Design, setting, and participants: This was a multi-institutional, retrospective analysis of 506 (SBRT: 309, ENRT: 197) patients with hormone-sensitive nodal oligorecurrent PC (five or fewer lymph nodes (LNs; N1/M1a), treated between 2004 and 2017. Median follow-up was 36 mo (interquartile range 23-56). Intervention: SBRT was defined as a minimum of 5 Gy per fraction to each lesion with a maximum of 10 fractions. ENRT was defined as a minimum dose of 45 Gy in up to 25 fractions to the elective nodes, with or without a simultaneous boost to the suspicious node(s). The choice of radiotherapy (RT) was at the discretion of the treating physician, with treatments being unbalanced over the centers. Outcome measurements and statistical analysis: In total, 506 patients from 15 different treatment centers were included. Primary treatment was radical prostatectomy, RT, or their combination. Nodal recurrences were detected by positron emission tomography/computer tomography (97%) or conventional imaging (3%). Descriptive statistics was used to summarize patient characteristics. Results and limitations: ENRT was associated with fewer nodal recurrences compared with SBRT (p

Published
2019

47. P046 - Comparing stereotactic body radiotherapy and elective nodal radiotherapy in the management of nodal oligorecurrent prostate cancer: a multi-institutional analysis.

Author

De Bleser, E., Jereczek-Fossa, B.A., Pasquier, D., Zilli, T., Van As, N., Siva, S., Fodor, A., Dirix, P., Gomez De Iturriaga, A., Trippa, F., Detti, B., Ingrosso, G., Triggiani, L., Alessio, B., Alongi, F., Fonteyne, V., Surgo, A., Loukili, K., Miralbell, R., and Pedro, S.

Subjects
*CANCER radiotherapy, *PROSTATE cancer, *RADIOISOTOPE brachytherapy, *STEREOTACTIC radiotherapy, *CANCER treatment
Published
2018
Full Text
View/download PDF

48. Can interventional radiotherapy (brachytherapy) be an alternative to surgery in early-stage oral cavity cancer? A systematic review.

Author

Draghini L, Lancellotta V, Fionda B, De Angeli M, Cornacchione P, Massaccesi M, Trippa F, Kovács G, Morganti AG, Bussu F, Iezzi R, and Tagliaferri L

Subjects
Humans, Neoplasm Staging, Disease-Free Survival, Treatment Outcome, Brachytherapy methods, Mouth Neoplasms radiotherapy
Abstract

Purpose: Brachytherapy (BT), also known as interventional radiotherapy (IRT), has proven its utility in the treatment of localized tumors. The aim of this review was to examine the efficacy of modern BT in early-stage oral cavity cancer (OCC) in terms of local control (LC), overall survival (OS), disease-free survival (DFS), cancer-specific survival (CSS), and safety., Methods: The SPIDER framework was used, with sample (S), phenomena of interest (PI), design (D), evaluation (E), and research type (R) corresponding to early-stage oral cavity cancer (S); BT (PI); named types of qualitative data collection and analysis (D); LC, OS, DFS, CSS, and toxicity (E); qualitative method (R). Systematic research using PubMed and Scopus was performed to identify full articles evaluating the efficacy of BT in patients with early-stage OCC. The studies were identified using medical subject headings (MeSH). We also performed a PubMed search with the keywords "brachytherapy oral cavity cancer, surgery." The search was restricted to the English language. The timeframe 2002-2022 as year of publication was considered. We analyzed clinical studies of patients with OCC treated with BT alone only as full text; conference papers, surveys, letters, editorials, book chapters, and reviews were excluded., Results: The literature search resulted in 517 articles. After the selection process, 7 studies fulfilled the inclusion criteria and were included in this review, totaling 456 patients with early-stage node-negative OCC who were treated with BT alone (304 patients). Five-year LC, DFS, and OS for the BT group were 60-100%, 82-91%, and 50-84%, respectively., Conclusion: In conclusion, our review suggests that BT is effective in the treatment of early-stage OCC, particularly for T1N0 of the lip, mobile tongue, and buccal mucosa cancers, with good functional and toxicity profiles., (© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.)

Published
2024
Full Text
View/download PDF

49. Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE).

Author

Ingrosso G, Ponti E, Francolini G, Caini S, Fondelli S, Santini R, Valeriani M, Rago L, Duroni G, Bruni A, Augurio A, Tramacere F, Trippa F, Russo D, Bottero M, Tamburo M, Parisi S, Borghesi S, Lancia A, Gomellini S, Scoccianti S, Stefanacci M, Vullo G, Statuto T, Miranda G, Santo B, Di Marzo A, Bellavita R, Vinciguerra A, Livi L, Aristei C, Bertini N, Orsatti C, and Detti B

Subjects
Male, Humans, Retrospective Studies, Androgen Antagonists, Prospective Studies, Neoplasm Recurrence, Local, Prostatic Neoplasms radiotherapy, Radiotherapy, Image-Guided methods, Radiotherapy, Intensity-Modulated methods
Abstract

Background: Moderate hypofractionated radiotherapy is a treatment option for the cure of localized prostate cancer (PCa) patients based on the results of randomized prospective trials, but there is a clinical concern about the relatively short length of follow-up, and real-world results on outcome and toxicity based on cutting-edge techniques are lacking. The objective of this study is to present the long-term results of a large multicentric series., Materials and Methods: We retrospectively evaluated 1325 PCa patients treated with daily volumetric image-guided hypofractionated radiotherapy between 2007 and 2020 in 16 Centers. For survival endpoints, we used Kaplan-Meier survival curves and fitted univariate and multivariable Cox's proportional hazards regression models to study the association between the clinical variables and each survival type., Results: At the end of the follow-up, 11 patients died from PCa. The 15-year values of cancer-specific survival (CSS) and biochemical relapse-free survival (b-RFS) were 98.5% (95%CI 97.3-99.6%) and 85.5% (95%CI 81.9-89.4%), respectively. The multivariate analysis showed that baseline PSA, Gleason score, and the use of androgen deprivation therapy were significant variables for all the outcomes. Acute gastrointestinal (GI) and genitourinary (GU) toxicities of grade ≥ 2 were 7.0% and 16.98%, respectively. The 15-year late grade ≥ 2 GI and GU toxicities were 5% (95%CI 4-6%) and 6% (95%CI 4-8%), respectively., Conclusion: Real-world long-term results of this multicentric study on cutting-edge techniques for the cure of localized PCa demonstrated an excellent biochemical-free survival rate of 85.5% at 15 years, and very low rates of ≥ G3 late GU and GI toxicity (1.6% and 0.9% respectively), strengthening the results of the available published trials., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

50. Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: A multi-institutional study.

Author

Cilla S, Campitelli M, Antonietta Gambacorta M, Michela Rinaldi R, Deodato F, Pezzulla D, Romano C, Fodor A, Laliscia C, Trippa F, De Sanctis V, Ippolito E, Ferioli M, Titone F, Russo D, Balcet V, Vicenzi L, Di Cataldo V, Raguso A, Giuseppe Morganti A, Ferrandina G, and Macchia G

Subjects
Humans, Machine Learning, Algorithms, Area Under Curve, Pathologic Complete Response, Radiosurgery, Neoplasms
Abstract

Background and Purpose: We aimed to develop and validate different machine-learning (ML) prediction models for the complete response of oligometastatic gynecological cancer after SBRT., Material and Methods: One hundred fifty-seven patients with 272 lesions from 14 different institutions and treated with SBRT with radical intent were included. Thirteen datasets including 222 lesions were combined for model training and internal validation purposes, with an 80:20 ratio. The external testing dataset was selected as the fourteenth Institution with 50 lesions. Lesions that achieved complete response (CR) were defined as responders. Prognostic clinical and dosimetric variables were selected using the LASSO algorithm. Six supervised ML models, including logistic regression (LR), classification and regression tree analysis (CART) and support vector machine (SVM) using four different kernels, were trained and tested to predict the complete response of uterine lesions after SBRT. The performance of models was assessed by receiver operating characteristic curves (ROC), area under the curve (AUC) and calibration curves. An explainable approach based on SHapley Additive exPlanations (SHAP) method was deployed to generate individual explanations of the model's decisions., Results: 63.6% of lesions had a complete response and were used as ground truth for the supervised models. LASSO strongly associated complete response with three variables, namely the lesion volume (PTV), the type of lesions (lymph-nodal versus parenchymal), and the biological effective dose (BED 10 ), that were used as input for ML modeling. In the training set, the AUCs for complete response were 0.751 (95% CI: 0.716-0.786), 0.766 (95% CI: 0.729-0.802) and 0.800 (95% CI: 0.742-0.857) for the LR, CART and SVM with a radial basis function kernel, respectively. These models achieve AUC values of 0.727 (95% CI: 0.669-0.795), 0.734 (95% CI: 0.649-0.815) and 0.771 (95% CI: 0.717-0.824) in the external testing set, demonstrating excellent generalizability., Conclusion: ML models enable a reliable prediction of the treatment response of oligometastatic lesions receiving SBRT. This approach may assist radiation oncologists to tailor more individualized treatment plans for oligometastatic patients., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results